GTX higher on Capesaris trial results

|By:, SA News Editor

GTX (GTXI) races higher in early trading in front of a presentation on positive results from a Phase 2 clinical trial on the company's prostrate cancer treatment Capesaris.

GTXI +13.8% premarket